Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pressure intensifies on UK to increase vCJD testing

This article was originally published in Clinica

Executive Summary

UK spongiform encephalopathy experts have quantified in terms of incidence levels their growing concerns that one or more waves of variant Creutzfeldt-Jakob disease (vCJD) may yet arise as a result of new patterns of genetic susceptibility. But the main implication of the development is the increased urgency of developing a diagnostic to screen for the disease in asymptomatic carriers, given that, instead of the risk of infectivity tailing off, there could be a significant additional proportion of carriers in the population.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT043230

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel